1-7 of 7
Leanne Lash
Close
Sort by
Journal Articles

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

Cesar Rodriguez, Katja Weisel, Rachid C. Baz, Akshanth R. Polepally, Jeremy A. Ross, Ziyi Jin, Kristin D'Amico, Orlando F. Bueno, Leanne Lash Fleming, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 7326–7327.
https://doi.org/10.1182/blood-2022-157977
Published: 2022
Journal Articles

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid C. Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A. Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis
Journal: Blood
Blood (2022) 140 (Supplement 1): 7261–7263.
https://doi.org/10.1182/blood-2022-163809
Published: 2022
Journal Articles

Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone

Mohamed A Badawi, Benjamin Engelhardt, Jesus Badillo, Ahmed Abbas Suleiman, Leanne Lash Fleming, Yan Luo, Jonathan L. Kaufman, Nizar Jacques Bahlis, Rajeev Menon, Ahmed Hamed Salem
Journal: Blood
Blood (2022) 140 (Supplement 1): 10122–10123.
https://doi.org/10.1182/blood-2022-166429
Published: 2022
Journal Articles

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid Baz, Annette J. Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Vasudha Sehgal, Kingston Kang, Jeremy A. Ross, L. Leanne Lash-Fleming, Yan Luo, Nizar J. Bahlis
Journal: Blood
Blood (2021) 138 (Supplement 1): 817.
https://doi.org/10.1182/blood-2021-146043
Published: 2021
Journal Articles

Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

William G Wierda, MD PhD, John F Seymour, MBBS, PhD, Andrew W. Roberts, Su Young Kim, L. Leanne Lash-Fleming, Johnathan Maher, Todd Busman, Lang Zhou, Jacqueline Nielsen, Stephan Stilgenbauer, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4329.
https://doi.org/10.1182/blood.V130.Suppl_1.4329.4329
Published: 2017
Journal Articles

Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Danielle M. Brander, MD, Michael Y. Choi, MD, Andrew W. Roberts, Shuo Ma, L. Leanne Lash, Maria Verdugo, Ming Zhu, Su Young Kim, John F Seymour
Journal: Blood
Blood (2016) 128 (22): 2033.
https://doi.org/10.1182/blood.V128.22.2033.2033
Published: 2016
Journal Articles

Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Andrew W. Roberts, John F Seymour, Barbara Eichhorst, MD, Stephan Stilgenbauer, Michael Y. Choi, MD, Matthew S. Davids, John F. Gerecitano, Relja Popovic, Brenda Chyla, Ming Zhu, Maria Verdugo, Jalaja Potluri, Leanne Lash, Su Young Kim, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 3230.
https://doi.org/10.1182/blood.V128.22.3230.3230
Published: 2016